The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
The purpose of this study is to conduct a Hybrid Type 1 cluster-randomized, roll-out effectiveness-implementation trial in NCORP community oncology practice sites (N= 500 Black and Latino cancer patients) to evaluate the effectiveness of the EA SUPPORT intervention combining CT navigators and CT research literacy tools in improving Black and Latino patient referral and accrual to NCI-supported CTs (primary outcomes) and participant and provider awareness and knowledge of CTs (secondary outcomes) while assessing implementation factors. Also, with the CUSP2CT data, Evaluation, and Coordinating Center, conduct final site evaluation and disseminate the SUPPORT intervention to NCORP community oncology sites, research bases, and affiliated trial networks.
The purpose of this study is to conduct a Hybrid Type 1 cluster-randomized, roll-out effectiveness-implementation trial in NCORP community oncology practice sites (N= 500 Black and Latino cancer patients) to evaluate the effectiveness of the EA SUPPORT intervention combining CT navigators and CT research literacy tools in improving Black and Latino patient referral and accrual to NCI-supported CTs (primary outcomes) and participant and provider awareness and knowledge of CTs (secondary outcomes) while assessing implementation factors. Also, with the CUSP2CT data, Evaluation, and Coordinating Center, conduct final site evaluation and disseminate the SUPPORT intervention to NCORP community oncology sites, research bases, and affiliated trial networks.
Inclusion Criteria:
Participant must be ≥ 18 years of age. Participant must self-identify as Black and/or Latino. Participant must be an oncology patient at a participating NCORP. Participant must be eligible to participate in an ECOG-ACRIN clinical trial. Participant must have the ability to understand and the willingness to sign a e-consent document.
Participant must be receiving care at a participating NCORP affiliated community oncology site.
Participant must be English or Spanish speaking to be eligible. Participant must have access to a landline, smartphone, computer, or tablet.
Exclusion Criteria:
-
m-simon2@northwestern.edu(312) 503-8780
epark@mgh.harvard.edu(617) 724-6836
Jonesboro, Arkansas 72401, United States
Emily.Carvell@bmhcc.org870-936-7066
Savannah, Georgia 31405, United States
Columbus, Mississippi 39705, United States
New Albany, Mississippi 38652, United States
Oxford, Mississippi 38655, United States
Southhaven, Mississippi 38671, United States
Hazleton, Pennsylvania 18201, United States
Wilkes-Barre, Pennsylvania 18711, United States
Hilton Head Island, South Carolina 29926-3827, United States
Hilton Head Island, South Carolina 29926, United States
Collierville, Tennessee 38017, United States
Memphis, Tennessee 38120, United States
Summit, Wisconsin 53066, United States
ncorp@aurora.org414-302-2304
Oncologyresearch@sjchs.org912-819-5704
Oncologyresearch@sjchs.org912-819-5704
underberga@sjchs.org912-819-5704
RCMC_Cancer_Research@rush.edu630-978-6212
847-842-4847
Research@Carle.com800-446-5532
773-296-5360
advocateresearch@advocate.com630-929-6129
Research@Carle.com800-446-5532
Barbara.barhamand@advocatehealth.com630-275-1270
Research@carle.com800-446-5532
847-429-2907
708-799-9995
advocateresearch@advocatehealth.com630-929-6129
advocateresearch@advocatehealth.com630-929-6129
Research@carle.com800-446-5532
Research@Carle.com800-446-5532
Research@Carle.com800-446-5532
800-323-8622
ncorp@aah.org
847-384-3621
Research@carle.com800-446-5532
Cancer.Research@rushcopley.com630-978-6212
BCCclintrials@bmhcc.org901-226-1366
BCCclintrials@bmhcc.org901-226-1366
BCCclintrials@bmhcc.org901-226-1366
BCCclintrials@bmhcc.org901-226-1366
BCCclintrials@bmhcc.org901-226-1366
eskwak@montefiore.org718-379-6866
eskwak@montefiore.org718-379-6866
HemonCCTrials@geisinger.edu570-271-5251
hemoncctrials@geisinger.edu877-204-6081
HemonCCTrials@geisinger.edu570-459-2901
HemonCCTrials@geisinger.edu570-374-8555
HemonCCTrials@geisinger.edu800-275-6401
HemonCCTrials@geisinger.edu570-703-4768
HemonCCTrials@geisinger.edu570-271-5251
underberga@sjchs.org912-819-5704
underberga@sjchs.org912-819-5704
underberga@sjchs.org912-819-5704
BCCclintrials@bmhcc.org901-226-1366
BCCclintrials@bmhcc.org901-226-1366
BCCclintrials@bmhcc.org901-226-1366
anne_carmellat@bshsi.org804-893-8978
anne_carmellat@bshsi.org804-893-8978
anne_carmellat@bshsi.org804-893-8978
anne_carmellat@bshsi.org804-893-8978
anne_carmellat@bshsi.org804-893-8978
Anne_caramella@bshsi.org804-893-8978
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304
ncorp@aurora.org414-302-2304